Advertisement

Antimicrobial Stewardship: Considerations for a Cancer Center

  • Coralia N. Mihu
  • Alla Paskovaty
  • Susan K. Seo
Chapter
Part of the Current Clinical Oncology book series (CCO)

Abstract

Since the discovery of penicillin, unbridled enthusiasm for antibiotics has led to their extensive application in medicine, animal care, and agriculture. Injudicious antimicrobial use has also contributed to the emergence and spread of multidrug-resistant bacteria, creating a situation in which there are few or no treatment options for infections due to these organisms. There is increasing awareness that antimicrobial resistance adversely impacts patient safety and public health. In essence, effective antimicrobial stewardship entails the optimal selection, dose, and duration of an antibiotic, resulting in the cure of an infection with minimal toxicity to the patient and minimal impact on selective pressure. A detailed discussion on this important issue is presented in this chapter.

Keywords

Multidrug-resistant bacteria Injudicious antimicrobial use Optimal antibiotic selection Duration of antibiotic therapy Reduced drug toxicity 

References

  1. 1.
    Levy S. The antibiotic paradox: how the misuse of antibiotics destroys their curative powers. 2nd ed. Cambridge: Perseus Publishing; 2002.Google Scholar
  2. 2.
    Yu VL, Stoehr GP, Starling RC, Shogan JE. Empiric antibiotic selection by physicians: evaluation of reasoning strategies. Am J Med Sci. 1991;301:165–72.PubMedCrossRefGoogle Scholar
  3. 3.
    Gonzales R, Malone DC, Maselli JH, Sande MA. Excessive antibiotic use for acute respiratory infections in the United States. Clin Infect Dis. 2001;33:757–62.PubMedCrossRefGoogle Scholar
  4. 4.
    Lemmen SW, Becker G, Frank U, Daschner FD. Influence of an infectious disease consulting service on quality and costs of antibiotic prescriptions in a university hospital. Scand J Infect Dis. 2001;33:219–21.PubMedCrossRefGoogle Scholar
  5. 5.
    Erbay A, Colpan A, Bodur H, Cevik MA, Samore MH, Ergonul O. Evaluation of antibiotic use in a hospital with an antibiotic restriction policy. Int J Antimicrob Agents. 2003;21:308–12.PubMedCrossRefGoogle Scholar
  6. 6.
    Pear SM, Williamson TH, Bettin KM, Gerding DN, Galgiani JN. Decrease in nosocomial Clostridium difficile-associated diarrhea by restricting clindamycin use. Ann Intern Med. 1994;120:272–7.PubMedCrossRefGoogle Scholar
  7. 7.
    McNulty C, Logan M, Donald IP, et al. Successful control of Clostridium difficile infection in an elderly care unit through use of a restrictive antibiotic policy. J Antimicrob Chemother. 1997;40:707–11.PubMedCrossRefGoogle Scholar
  8. 8.
    Climo MW, Israel DS, Wong ES, Williams D, Coudron P, Markowitz SM. Hospital-wide restriction of clindamycin: effect on the ­incidence of Clostridium difficile-associated diarrhea and cost. Ann Intern Med. 1998;128:989–95.PubMedCrossRefGoogle Scholar
  9. 9.
    Muto CA, Pokrywka M, Shutt K, et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol. 2005;26:273–80.PubMedCrossRefGoogle Scholar
  10. 10.
    Pepin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis. 2005;41:1254–60.PubMedCrossRefGoogle Scholar
  11. 11.
    Owens Jr RC, Donskey CJ, Gaynes RP, Loo VG, Muto CA. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis. 2008;46 Suppl 1:S19–31.PubMedCrossRefGoogle Scholar
  12. 12.
    Anthony KB, Fishman NO, Linkin DR, Gasink LB, Edelstein PH, Lautenbach E. Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline. Clin Infect Dis. 2008;46:567–70.PubMedCrossRefGoogle Scholar
  13. 13.
    Scheetz MH, Knechtel SA, Malczynski M, Postelnick MJ, Qi C. Increasing incidence of linezolid-intermediate or -resistant, vancomycin-resistant Enterococcus faecium strains parallels increasing linezolid consumption. Antimicrob Agents Chemother. 2008;52:2256–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Payne D, Tomasz A. The challenge of antibiotic resistant bacterial pathogens: the medical need, the market and prospects for new antimicrobial agents. Curr Opin Microbiol. 2004;7:435–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Spellberg B, Powers JH, Brass EP, Miller LG, Edwards Jr JE. Trends in antimicrobial drug development: implications for the future. Clin Infect Dis. 2004;38:1279–86.PubMedCrossRefGoogle Scholar
  16. 16.
    Thomson CJ, Power E, Ruebsamen-Waigmann H, Labischinski H. Antibacterial research and development in the 21(st) Century–an industry perspective of the challenges. Curr Opin Microbiol. 2004;7:445–50.PubMedCrossRefGoogle Scholar
  17. 17.
    Centers for Disease Control and Prevention (CDC). High levels of adamantane resistance among influenza A (H3N2) viruses and interim guidelines for use of antiviral agents – United States, 2005–06 influenza season. MMWR Morb Mortal Wkly Rep. 2006;55:44–6.Google Scholar
  18. 18.
    Morfin F, Thouvenot D. Herpes simplex virus resistance to antiviral drugs. J Clin Virol. 2003;26:29–37.PubMedCrossRefGoogle Scholar
  19. 19.
    Chou S. Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir. Rev Med Virol. 2008;18:233–46.PubMedCrossRefGoogle Scholar
  20. 20.
    Vanden Bossche H, Dromer F, Improvisi I, Lozano-Chiu M, Rex JH, Sanglard D. Antifungal drug resistance in pathogenic fungi. Med Mycol. 1998;36 Suppl 1:119–28.Google Scholar
  21. 21.
    Upcroft P, Upcroft JA. Drug targets and mechanisms of resistance in the anaerobic protozoa. Clin Microbiol Rev. 2001;14:150–64.PubMedCrossRefGoogle Scholar
  22. 22.
    Plowe CV. The evolution of drug-resistant malaria. Trans R Soc Trop Med Hyg. 2009;103:S11–4.PubMedCrossRefGoogle Scholar
  23. 23.
    Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest. 2000;118:146–55.PubMedCrossRefGoogle Scholar
  24. 24.
    Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis. 2001;32:1162–71.PubMedCrossRefGoogle Scholar
  25. 25.
    Bhavnani SM, Drake JA, Forrest A, et al. A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia. Diagn Microbiol Infect Dis. 2000;36:145–58.PubMedCrossRefGoogle Scholar
  26. 26.
    Carmeli Y, Eliopoulos G, Mozaffari E, Samore M. Health and economic outcomes of vancomycin-resistant enterococci. Arch Intern Med. 2002;162:2223–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Cosgrove SE, Kaye KS, Eliopoulous GM, Carmeli Y. Health and economic outcomes of the emergence of third-generation ­cephalosporin resistance in Enterobacter species. Arch Intern Med. 2002;162:185–90.PubMedCrossRefGoogle Scholar
  28. 28.
    Engemann JJ, Carmeli Y, Cosgrove SE, et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis. 2003;36:592–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Institute of Medicine. Antimicrobial drug resistance: issues and options. Workshop report. Washington: National Academy Press; 1998.Google Scholar
  30. 30.
    Shehab N, Patel PR, Srinivasan A, Budnitz DS. Emergency department visits for antibiotic-associated adverse events. Clin Infect Dis. 2008;47:735–43.PubMedCrossRefGoogle Scholar
  31. 31.
    Shlaes DM, Gerding DN, John Jr JF, et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Infect Control Hosp Epidemiol. 1997;18:275–91.PubMedCrossRefGoogle Scholar
  32. 32.
    Polk R. Optimal use of modern antibiotics: emerging trends. Clin Infect Dis. 1999;29:264–74.PubMedCrossRefGoogle Scholar
  33. 33.
    Klapp DL, Ramphal R. Antibiotic restriction in hospitals associated with medical schools. Am J Hosp Pharm. 1983;40:1957–60.PubMedGoogle Scholar
  34. 34.
    Lesar TS, Briceland LL. Survey of antibiotic control policies in university-affiliated teaching institutions. Ann Pharmacother. 1996;30:31–4.PubMedGoogle Scholar
  35. 35.
    Lawton RM, Fridkin SK, Gaynes RP, McGowan Jr JE. Practices to improve antimicrobial use at 47 US hospitals: the status of the 1997 SHEA/IDSA position paper recommendations. Society for Healthcare Epidemiology of America/Infectious Diseases Society of America. Infect Control Hosp Epidemiol. 2000;21:256–9.PubMedCrossRefGoogle Scholar
  36. 36.
    Moro ML, Petrosillo N, Gandin C. Antibiotic policies in Italian hospitals: still a lot to achieve. Microb Drug Resist. 2003;9:219–22.PubMedCrossRefGoogle Scholar
  37. 37.
    Woodford EM, Wilson KA, Marriott JF. Documentation of antibiotic prescribing controls in UK NHS hospitals. J Antimicrob Chemother. 2004;53:650–2.PubMedCrossRefGoogle Scholar
  38. 38.
    Dellit TH, Owens RC, McGowan Jr JE, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007;44:159–77.PubMedCrossRefGoogle Scholar
  39. 39.
    Paskovaty A, Pflomm JM, Myke N, Seo SK. A multidisciplinary approach to antimicrobial stewardship: evolution into the 21st century. Int J Antimicrob Agents. 2005;25:1–10.PubMedCrossRefGoogle Scholar
  40. 40.
    Couriel D, Saliba R, Hicks K, et al. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood. 2004;104: 649–54.PubMedCrossRefGoogle Scholar
  41. 41.
    Virchis A, Koh M, Rankin P, et al. Fludarabine, cytosine arabinoside, granulocyte-colony stimulating factor with or without idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromes. Br J Haematol. 2004;124:26–32.PubMedCrossRefGoogle Scholar
  42. 42.
    Martin SI, Marty FM, Fiumara K, Treon SP, Gribben JG, Baden LR. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis. 2006;43:16–24.PubMedCrossRefGoogle Scholar
  43. 43.
    Fraser GL, Stogsdill P, Dickens Jr JD, Wennberg DE, Smith Jr RP, Prato BS. Antibiotic optimization. An evaluation of patient safety and economic outcomes. Arch Intern Med. 1997;157:1689–94.PubMedCrossRefGoogle Scholar
  44. 44.
    Gross R, Morgan AS, Kinky DE, Weiner M, Gibson GA, Fishman NO. Impact of a hospital-based antimicrobial management program on clinical and economic outcomes. Clin Infect Dis. 2001;33:289–95.PubMedCrossRefGoogle Scholar
  45. 45.
    Carling P, Fung T, Killion A, Terrin N, Barza M. Favorable impact of a multidisciplinary antibiotic management program conducted during 7 years. Infect Control Hosp Epidemiol. 2003;24:699–706.PubMedCrossRefGoogle Scholar
  46. 46.
    LaRocco Jr A. Concurrent antibiotic review programs – a role for infectious diseases specialists at small community hospitals. Clin Infect Dis. 2003;37:742–3.PubMedCrossRefGoogle Scholar
  47. 47.
    Lutters M, Harbarth S, Janssens JP, et al. Effect of a comprehensive, multidisciplinary, educational program on the use of antibiotics in a geriatric university hospital. J Am Geriatr Soc. 2004;52:112–6.PubMedCrossRefGoogle Scholar
  48. 48.
    Burke JP. Infection control – a problem for patient safety. N Engl J Med. 2003;348:651–6.PubMedCrossRefGoogle Scholar
  49. 49.
    John Jr JF, Fishman NO. Programmatic role of the infectious diseases physician in controlling antimicrobial costs in the hospital. Clin Infect Dis. 1997;24:471–85.PubMedCrossRefGoogle Scholar
  50. 50.
    Pestotnik SL, Classen DC, Evans RS, Burke JP. Implementing ­antibiotic practice guidelines through computer-assisted decision support: clinical and financial outcomes. Ann Intern Med. 1996;124: 884–90.PubMedCrossRefGoogle Scholar
  51. 51.
    Evans RS, Pestotnik SL, Classen DC, et al. A computer-assisted management program for antibiotics and other antiinfective agents. N Engl J Med. 1998;338:232–8.PubMedCrossRefGoogle Scholar
  52. 52.
    Evans RS, Pestotnik SL, Classen DC, Burke JP. Evaluation of a computer-assisted antibiotic-dose monitor. Ann Pharmacother. 1999;33:1026–31.PubMedCrossRefGoogle Scholar
  53. 53.
    Mullett CJ, Evans RS, Christenson JC, Dean JM. Development and impact of a computerized pediatric antiinfective decision support program. Pediatrics. 2001;108:E75.PubMedCrossRefGoogle Scholar
  54. 54.
    Struelens MJ. Multidisciplinary antimicrobial management teams: the way forward to control antimicrobial resistance in hospitals. Curr Opin Infect Dis. 2003;16:305–7.PubMedCrossRefGoogle Scholar
  55. 55.
    Procop GW, Winn W. Outsourcing microbiology and offsite laboratories. Implications on patient care, cost savings, and graduate medical education. Arch Pathol Lab Med. 2003;127:623–4.PubMedGoogle Scholar
  56. 56.
    Burke JP, Pestotnik SL. Antibiotic use and microbial resistance in intensive care units: impact of computer-assisted decision support. J Chemother. 1999;11:530–5.PubMedGoogle Scholar
  57. 57.
    Binkley S, Fishman NO, LaRosa LA, et al. Comparison of unit-specific and hospital-wide antibiograms: potential implications for selection of empirical antimicrobial therapy. Infect Control Hosp Epidemiol. 2006;27:682–7.PubMedCrossRefGoogle Scholar
  58. 58.
    Forrest G. Role of antifungal susceptibility testing in patient management. Curr Opin Infect Dis. 2006;19:538–43.PubMedCrossRefGoogle Scholar
  59. 59.
    Arikan S. Current status of antifungal susceptibility testing methods. Med Mycol. 2007;45:569–87.PubMedCrossRefGoogle Scholar
  60. 60.
    Marr JJ, Moffet HL, Kunin CM. Guidelines for improving the use of antimicrobial agents in hospitals: a statement by the Infectious Diseases Society of America. J Infect Dis. 1988;157:869–76.PubMedCrossRefGoogle Scholar
  61. 61.
    Crowe HM, Quintiliani R. Antibiotic formulary selection. Med Clin North Am. 1995;79:463–76.PubMedGoogle Scholar
  62. 62.
    Woodward RS, Medoff G, Smith MD, Gray 3rd JL. Antibiotic cost savings from formulary restrictions and physician monitoring in a medical-school-affiliated hospital. Am J Med. 1987;83:817–23.PubMedCrossRefGoogle Scholar
  63. 63.
    Coleman RW, Rodondi LC, Kaubisch S, Granzella NB, O’Hanley PD. Cost-effectiveness of prospective and continuous parenteral antibiotic control: experience at the Palo Alto Veterans Affairs Medical Center from 1987 to 1989. Am J Med. 1991;90:439–44.PubMedGoogle Scholar
  64. 64.
    Maswoswe JJ, Okpara AU. Enforcing a policy for restricting antimicrobial drug use. Am J Health Syst Pharm. 1995;52:1433–5.PubMedGoogle Scholar
  65. 65.
    White Jr AC, Atmar RL, Wilson J, Cate TR, Stager CE, Greenberg SB. Effects of requiring prior authorization for selected antimicrobials: expenditures, susceptibilities, and clinical outcomes. Clin Infect Dis. 1997;25:230–9.PubMedCrossRefGoogle Scholar
  66. 66.
    Schentag JJ, Ballow CH, Fritz AL, et al. Changes in antimicrobial agent usage resulting from interactions among clinical pharmacy, the infectious disease division, and the microbiology laboratory. Diagn Microbiol Infect Dis. 1993;16:255–64.PubMedCrossRefGoogle Scholar
  67. 67.
    Solomon DH, Van Houten L, Glynn RJ, et al. Academic detailing to improve use of broad-spectrum antibiotics at an academic medical center. Arch Intern Med. 2001;161:1897–902.PubMedCrossRefGoogle Scholar
  68. 68.
    Bearden DT, Allen GP. Impact of antimicrobial control programs on patient outcomes. Pharmacy perspective. Dis Manage Health Outcomes. 2003;11:723–36.CrossRefGoogle Scholar
  69. 69.
    Grimshaw JM, Shirran L, Thomas R, et al. Changing provider behavior: an overview of systematic reviews of interventions. Med Care. 2001;39:II2–45.Google Scholar
  70. 70.
    Gray J. Changing physician prescribing behaviour. Can J Clin Pharmacol. 2006;13:e81–4.PubMedGoogle Scholar
  71. 71.
    Girotti MJ, Fodoruk S, Irvine-Meek J, Rotstein OD. Antibiotic handbook and pre-printed perioperative order forms for surgical antibiotic prophylaxis: do they work? Can J Surg. 1990;33:385–8.PubMedGoogle Scholar
  72. 72.
    Bantar C, Sartori B, Vesco E, et al. A hospitalwide intervention program to optimize the quality of antibiotic use: impact on prescribing practice, antibiotic consumption, cost savings, and bacterial resistance. Clin Infect Dis. 2003;37:180–6.PubMedCrossRefGoogle Scholar
  73. 73.
    Belongia EA, Knobloch MJ, Kieke BA, Davis JP, Janette C, Besser RE. Impact of statewide program to promote appropriate antimicrobial drug use. Emerg Infect Dis. 2005;11:912–20.PubMedCrossRefGoogle Scholar
  74. 74.
    Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34:730–51.PubMedCrossRefGoogle Scholar
  75. 75.
    Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm Rep. 2000;49:1–125; CE1–7.Google Scholar
  76. 76.
    Sullivan KM, Dykewicz CA, Longworth DL, et al. Preventing opportunistic infections after hematopoietic stem cell transplantation: the Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation Practice Guidelines and beyond. Hematology Am Soc Hematol Educ Program. 2001;1:392–421.CrossRefGoogle Scholar
  77. 77.
    Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46:327–60.PubMedCrossRefGoogle Scholar
  78. 78.
    Rex JH, Walsh TJ, Sobel JD, et al. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis. 2000;30:662–78.PubMedCrossRefGoogle Scholar
  79. 79.
    ASHP Therapeutic Guidelines on Antimicrobial Prophylaxis in Surgery. American society of health-system pharmacists. Am J Health Syst Pharm. 1999;56:1839–88.Google Scholar
  80. 80.
    Bratzler DW, Houck PM. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Clin Infect Dis. 2004;38:1706–15.PubMedCrossRefGoogle Scholar
  81. 81.
    Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA. 2003;290:2588–98.PubMedCrossRefGoogle Scholar
  82. 82.
    Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med. 2000;162: 505–11.PubMedCrossRefGoogle Scholar
  83. 83.
    Kollef MH, Kollef KE. Antibiotic utilization and outcomes for patients with clinically suspected ventilator-associated pneumonia and negative quantitative BAL culture results. Chest. 2005;128: 2706–13.PubMedCrossRefGoogle Scholar
  84. 84.
    Briceland LL, Nightingale CH, Quintiliani R, Cooper BW, Smith KS. Antibiotic streamlining from combination therapy to monotherapy utilizing an interdisciplinary approach. Arch Intern Med. 1988;148:2019–22.PubMedCrossRefGoogle Scholar
  85. 85.
    Glowacki RC, Schwartz DN, Itokazu GS, Wisniewski MF, Kieszkowski P, Weinstein RA. Antibiotic combinations with redundant antimicrobial spectra: clinical epidemiology and pilot intervention of computer-assisted surveillance. Clin Infect Dis. 2003;37: 59–64.PubMedCrossRefGoogle Scholar
  86. 86.
    Lelekis M, Gould IM. Sequential antibiotic therapy for cost containment in the hospital setting: why not? J Hosp Infect. 2001;48: 249–57.PubMedCrossRefGoogle Scholar
  87. 87.
    Drew RH. Programs promoting timely sequential antimicrobial therapy: an American perspective. J Infect. 1998;37 Suppl 1:3–9.PubMedCrossRefGoogle Scholar
  88. 88.
    Amodio-Groton M, Madu A, Madu CN, et al. Sequential parenteral and oral ciprofloxacin regimen versus parenteral therapy for bacteremia: a pharmacoeconomic analysis. Ann Pharmacother. 1996;30: 596–602.PubMedGoogle Scholar
  89. 89.
    Sevinc F, Prins JM, Koopmans RP, et al. Early switch from intravenous to oral antibiotics: guidelines and implementation in a large teaching hospital. J Antimicrob Chemother. 1999;43:601–6.PubMedCrossRefGoogle Scholar
  90. 90.
    Ramirez JA, Bordon J. Early switch from intravenous to oral antibiotics in hospitalized patients with bacteremic community-acquired Streptococcus pneumoniae pneumonia. Arch Intern Med. 2001;161: 848–50.PubMedCrossRefGoogle Scholar
  91. 91.
    Wong-Beringer A, Nguyen KH, Razeghi J. Implementing a program for switching from i.v. to oral antimicrobial therapy. Am J Health Syst Pharm. 2001;58:1146–9.PubMedGoogle Scholar
  92. 92.
    Sunenshine RH, Liedtke LA, Jernigan DB, Strausbaugh LJ. Role of infectious diseases consultants in management of antimicrobial use in hospitals. Clin Infect Dis. 2004;38:934–8.PubMedCrossRefGoogle Scholar
  93. 93.
    Rapp RP. Pharmacy infectious diseases practice. Ann Pharmacother. 2006;40:304–6.PubMedCrossRefGoogle Scholar
  94. 94.
    McQuillen DP, Petrak RM, Wasserman RB, Nahass RG, Scull JA, Martinelli LP. The value of infectious diseases specialists: non-patient care activities. Clin Infect Dis. 2008;47:1051–63.PubMedCrossRefGoogle Scholar
  95. 95.
    Rybak MJ. Antimicrobial stewardship. Pharmacotherapy. 2007;27:131S–5S.PubMedCrossRefGoogle Scholar
  96. 96.
    Phillips I. Prudent use of antibiotics: are our expectations justified? Clin Infect Dis. 2001;33 Suppl 3:S130–2.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Department of Infectious Diseases, Infection Control and Employee HealthThe University of Texas M.D. AndersonHoustonUSA

Personalised recommendations